Skip to content
Screener

Embecta Corp. EMBC EPS (Diluted)

EPS (Diluted) at other companies

Insulet logo
InsuletPODD
$1.37+328%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$0.31+60.3%
Medtronic logo
MedtronicMDT
$0.97+18.3%
KORU Medical Systems logo
KORU Medical SystemsKRMD
$0.01
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$0.05+600%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$0.19

Other financials

Income statement

See full
Revenue$271.7M-8.1%
Gross profit$153.3M-22.2%
Operating income$48.7M-48.2%
Net income$21.1M-53.6%

Balance sheet

See full
Cash & equivalents$218.2M-6.6%
Total debt$1.5B-1.0%
Total equity-$612.7M+8.5%
Total assets$1.3B+9.3%

Cash flow

See full
Operating cash flow$41.8M-48.5%
CapEx$1.1M+175%
Free cash flow$40.7M-49.6%

Valuation

See full
Market cap$281.03M-67.1%
Enterprise value$1.56B-26.8%
P/E3.2×-7.0×
P/S0.3×-0.5×

Profitability

See full
Gross margin59%-3.7pp
Operating margin21.9%+2.7pp
Net margin8.6%+1.0pp
FCF margin16.2%+4.2pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Embecta Corp.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 2:28 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001872789-26-000033
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Nine Months Ended June 30, 2026Nine Months Ended June 30, 2025
Interest expense, net(23.9)(26.6)(70.6)(81.2)
Other income (expense), net2.84.8(0.4)2.9
Income Before Income Taxes$27.6$72.2$96.0$107.3
Income tax provision6.526.734.938.3
Net Income$21.1$45.5$61.1$69.0
Net Income per common share:
Basic$0.36$0.78$1.04$1.18
Diluted$0.36$0.78$1.03$1.18

Item 1. Financial Statements (Unaudited)

FAQ

What is Embecta Corp.'s EPS (diluted)?
Embecta Corp. (EMBC) reported EPS (diluted) of $0.36 in Q2 2026.
How has Embecta Corp.'s EPS (diluted) changed year-over-year?
Embecta Corp.'s EPS (diluted) decreased by 53.8% year-over-year, from $0.78 to $0.36.
What is the long-term trend for Embecta Corp.'s EPS (diluted)?
Over 4 years (2021 to 2025), Embecta Corp.'s EPS (diluted) has grown at a -31.3% compound annual growth rate (CAGR), from $7.28 to $1.62.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Embecta Corp.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude